IceCure Medical initiated the ChoICE post‑marketing study at the West Cancer Center & Research Institute to assess ProSense® cryoablation for low‑risk breast cancer. The study will provide clinical data that may influence reimbursement policies and increase uptake of cryoablation as a breast‑cancer treatment option. Who is involved: IceCure Medical (Nasdaq: ICCM), West Cancer Center & Research Institute, patients with low‑risk breast cancer.. Likely next: Enrollment of patients will proceed, with interim data expected in 2027 and full study results anticipated by the end of the decade.. IceCure Medical announced the start of its ChoICE post‑marketing study at the West Cancer Center & Research Institute, marking the first U.S. clinical site for evaluating its ProSense® cryoablation system in low‑risk breast cancer patients. The study aims to generate real‑world evidence that could support broader reimbursement and clinical adoption of the minimally invasive technology. This move follows IceCure’s recent expansion of its U.S. commercial team to address growing demand for its tumor‑ablation platform. Sectors affected: low-risk breast cancer cryoablation treatment market Historical parallels: IceCure expanded its U.S. commercial team on July 14, 2026 to meet surging demand for ProSense® cryoablation
INTELLIGENCE
Social Pulse
AI estimate · not scraped